scholarly journals Drug-Induced Lupus Erythematosus Associated with Antiretroviral Therapy in a Patient with Human Immunodeficiency Virus: A Case Report

Cureus ◽  
2017 ◽  
Author(s):  
Jazila Mantis ◽  
Ravi Bhavsar ◽  
Adriana Abrudescu
Keyword(s):  
Human Immunodeficiency Virus ◽  
Case Report ◽  
Antiretroviral Therapy ◽  
Lupus Erythematosus ◽  
Drug Induced ◽  
Immunodeficiency Virus

Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literature

2017 ◽  
Vol 29 (4) ◽  
pp. 414-417 ◽  
Author(s):  
Bo Wang ◽  
Laura Abbott ◽  
Kate Childs ◽  
Chris Taylor ◽  
Kosh Agarwal ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Case Report ◽  
Antiretroviral Therapy ◽  
Liver Injury ◽  
Liver Failure ◽  
Acute Liver Failure ◽  
Review Of Literature ◽  
Therapy Regimen ◽  
Immunodeficiency Virus ◽  
Human Immunodeficiency Virus 1

A patient with human immunodeficiency virus-1 infection presented with sub-acute liver failure, temporally related to commencement of an antiretroviral therapy regimen containing dolutegravir (Triumeq). The patient was not a carrier of HLA-B5701, and abacavir hypersensitivity was unlikely. We believe this is the first report of severe dolutegravir-related hepatotoxicity resulting in sub-acute liver failure and transplantation and highlights a potential need for closer monitoring after drug initiation.

scholarly journals Ten-year plateau phase in human immunodeficiency virus induced motor neuron disease upon antiretroviral therapy: a first case from Eastern Africa.

2020 ◽  
Vol 1 (5) ◽  
pp. 29-32
Author(s):  
Marjolein De Bruin ◽  
Emmanuel Assay ◽  
Asha Osman ◽  
Kajiru Kilonzo ◽  
William Howlett ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Case Report ◽  
Antiretroviral Therapy ◽  
Motor Neuron ◽  
Motor Neuron Disease ◽  
Sub Saharan Africa ◽  
Eastern Africa ◽  
First Case ◽  
Immunodeficiency Virus ◽  
Sub Saharan

We report an individual with rapidly progressive motor neuron disease (MND), phenotypically compatible with amyotrophic lateral sclerosis (ALS). The patient described in this case report proved positive for human immunodeficiency virus (HIV) and was initiated on antiretroviral therapy (ART). Following ART he clinically stabilised over 10 years and deteriorated again due to noncompliance or ART resistance. HIV infection can give rise to an MND mimic, HIV-ALS. The improvement in response to ART supports the notion that HIV-ALS is a treatable entity also in Africa. This is the first case report of a patient with HIV-ALS and long term follow up in Sub-Saharan Africa. The report raises the suggestion that an additional (retro)virus can play a role in the aetiology of ALS.

Human Immunodeficiency Virus: AIDS, the Current Plague

2020 ◽  
pp. 295-330
Author(s):  
Michael B. A. Oldstone
Keyword(s):  
Human Immunodeficiency Virus ◽  
Case Report ◽  
Drug Therapy ◽  
Antiretroviral Therapy ◽  
Death Rate ◽  
Medical Problems ◽  
Immunodeficiency Virus ◽  
Acquired Immunodeficiency ◽  
Long Course ◽  
Immunodeficiency Syndrome

This chapter explores acquired immunodeficiency syndrome (AIDS), a lethal disease cause by the human immunodeficiency virus (HIV). Of the more than 75 million people HIV has infected in the 36 years (1983–2019) since the initial case report, nearly one-half of them have died. Not only the victims of this infection but also their families, communities, countries, and even continents endured years of suffering as AIDS proceeded on its long course of physical destruction. Today, however, the enormous advance in antivirus drug therapy has dramatically reduced the death rate and altered the portrait of this disease from an acute lethal disease to a chronic persistent infection. In 2019, the combination antiretroviral therapy has enabled those infected to survive at roughly the same rate as the general non-infected population. However, this increased longevity includes an upsurge in the former group’s medical problems caused by the side effects of antiretroviral therapy. Despite an outlay of $1 billion per year for AIDS research, no vaccine is on the horizon for preventing this medical catastrophe.

HIV encephalitis in a patient on antiretroviral therapy: a case report

2019 ◽  
Vol 30 (6) ◽  
pp. 617-619 ◽  
Author(s):  
Maria Hlebowicz ◽  
Miłosz Parczewski ◽  
Paweł Jakubowski
Keyword(s):  
Human Immunodeficiency Virus ◽  
Drug Resistance ◽  
Cerebrospinal Fluid ◽  
Case Report ◽  
Antiretroviral Therapy ◽  
Viral Escape ◽  
Resistance Testing ◽  
Hiv Encephalitis ◽  
Hiv Resistance ◽  
Immunodeficiency Virus

We present the case of a 52-year-old man with human immunodeficiency virus (HIV) encephalitis resulting from cerebrospinal fluid (CSF) viral escape, to illustrate therapeutic challenges in patients with emergent CSF genotypic HIV drug resistance. This case report highlights the usefulness of CSF HIV-resistance testing to guide antiretroviral therapy and treatment optimizing decisions.

Sign in / Sign up

Export Citation Format

Share Document